The Microbiome Therapeutics Innovation Group (MTIG), a coalition of companies that research and develop FDA-approved microbiome therapeutics and microbiome-based products, revealed on Tuesday that Ken Blount PhD, chief scientific officer of Rebiotix Inc, has been appointed to the role of chairman.
MTIG stated that Dr Blount replaces Tom DesRosier Esq, chief legal officer of Seres Therapeutics, who served as MTIG Chairman since the inception of the coalition in 2018. DesRosier will continue to serve on the MTIG board of directors.
Pharmaceutical and biotechnology companies pursuing regulatory approvals for microbiome therapeutics and microbiome-based products are eligible for consideration of membership in MTIG, which is comprised of three microbiome therapeutics companies: Rebiotix, Inc, Seres Therapeutics and Vedanta Biosciences.
According to MTIG, the human microbiome is a new frontier of medical innovation that may benefit patients suffering from numerous diseases. The MTIG membership works together to enhance the regulatory, investment, and commercial environment to accelerate microbiome therapeutic product development and enable the field to fulfil its potential.
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business